Kendall
Kendall v. Odonate Therapeutics, Inc.
United States District Court, Southern District of CaliforniaJune 6, 20223:20-cv-01828California5,775 words
Opinion
Trial Court Opinion
UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF CALIFORNIA 13 KEVIN KENDALL, individually and on Case No.: 3:20-cv-01828-H-LL behalf of all others similarly situated,
ORDER:
Plaintiff, 16 v. (1) CERTIFYING SETTLEMENT
CLASS;
ODONATE THERAPEUTICS, INC.,
KEVIN C. TANG, MICHAEL HEARNE,
(2) GRANTING PLAINTIFF’S JOHN G. LEMKEY,
MOTION FOR FINAL
Defendants. APPROVAL OF CLASS ACTION SETTLEMENT; and
(3) GRANTING PLAINTIFF’S
MOTION FOR ATTORNEYS’
FEES, COSTS, AND INCENTIVE
AWARD
25 [Doc. Nos. 51, 52.] 26 On April 13, 2021, Plaintiff Kevin Kendall (“Plaintiff”) filed a second amended class action complaint against Defendants Odonate Therapeutics, Inc. (“Odonate”) and three of its officers, Kevin C. Tang, Michael Hearne, and John G. Lemkey (collectively “Defendants”) alleging violations of Section 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5. (Doc. No. 24, SAC ¶¶ 225–41.) On…